Obi Greenman
Chief Executive Officer en CERUS CORPORATION .
Fortuna: 6 M $ al 31/03/2024
Perfil
William Mariner Greenman is currently the President, Chief Executive Officer & Director at Cerus Corp.
He previously served as an Independent Director at Aduro BioTech, Inc. and Chinook Therapeutics, Inc. He also held the position of Senior Vice President-Biotech Division at Baxter International, Inc. Mr. Greenman obtained his undergraduate degree from Stanford University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CERUS CORPORATION
1.75% | 14/03/2024 | 3 181 281 ( 1.75% ) | 6 M $ | 31/03/2024 |
Cargos activos de Obi Greenman
| Empresas | Cargo | Inicio |
|---|---|---|
| CERUS CORPORATION | Chief Executive Officer | 21/04/2011 |
Antiguos cargos conocidos de Obi Greenman.
| Empresas | Cargo | Fin |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | 11/08/2023 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01/01/1995 |
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | - |
Formación de Obi Greenman.
| Stanford University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| CERUS CORPORATION | Health Technology |
| Empresas privadas | 2 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Obi Greenman
